CoChat

Alzheimer’s Disease

Scheltens, Philip, Blennow, Kaj, Breteler, Monique M B, de Strooper, Bart, Frisoni, Giovanni B, Salloway, Stephen, Van der Flier, Wiesje Maria · 2016 · The Lancet

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.

Abstract

Although the prevalence of dementia continues to increase worldwide, incidence in the western world might have decreased as a result of better vascular care and improved brain health. Alzheimer's disease, the most prevalent cause of dementia, is still defined by the combined presence of amyloid and tau, but researchers are gradually moving away from the simple assumption of linear causality as proposed in the original amyloid hypothesis. Age-related, protective, and disease-promoting factors probably interact with the core mechanisms of the disease. Amyloid β42, and tau proteins are established core cerebrospinal biomarkers; novel candidate biomarkers include amyloid β oligomers and synaptic markers. MRI and fluorodeoxyglucose PET are established imaging techniques for diagnosis of Alzheimer's disease. Amyloid PET is gaining traction in the clinical arena, but validity and cost-effectiveness remain to be established. Tau PET might offer new insights and be of great help in differential diagnosis and selection of patients for trials. In the search for understanding the disease mechanism and keys to treatment, research is moving increasingly into the earliest phase of disease. Preclinical Alzheimer's disease is defined as biomarker evidence of Alzheimer's pathological changes in cognitively healthy individuals. Patients with subjective cognitive decline have been identified as a useful population in whom to look for preclinical Alzheimer's disease. Moderately positive results f…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)01124-1

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

10 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 139 references

Research works printed but not linked: 2

  1. Welsh-Bohmer, 2014, Biomarker qualification for risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and safety and efficacy evaluation of pioglitazone in delaying its onset, J Prevent Alzheimer Dis, 3, 215
  2. Atri, 2014, A 5HT-6 antagonist in advanced development for the treatment of mild-moderate Alzheimer's disease, J Prevent Alzheimer Dis, 3, 220

Cited by

See all 3,125

Metadata

Authors
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M.
Affiliations
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • University of Gothenburg (SE)
  • University of Bonn (DE)
  • University of Geneva (CH)
  • Brown University (US)
Corresponding author
Scheltens, Philip
Venue
The Lancet
Publisher
Elsevier BV
Published
2016-07
Volume
388
Issue
10043
Pages
505-517
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4211213171
Cited by
3,125
References
139
Citations by year
2026: 162 · 2025: 286 · 2024: 336 · 2023: 308 · 2022: 369 · 2021: 397 · 2020: 361 · 2019: 324 · 2018: 314 · 2017: 199 · 2016: 67
FWCI
43.22
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, dementia, amyloid hypothesis, amyloid-beta, tau protein, cerebrospinal fluid biomarkers, amyloid PET, tau PET, preclinical Alzheimer's disease, subjective cognitive decline, lifestyle intervention, differential diagnosis
MeSH terms
Aged, Alzheimer Disease, Brain, Cognition, Female, Humans, Magnetic Resonance Imaging, Male, Neuropsychological Tests, Biomarkers, Amyloid beta-Peptides, tau Proteins, Radiopharmaceuticals, Fluorodeoxyglucose F18, Risk Reduction Behavior, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alzheimer’s Disease. https://app.cochat.ai/papers/10.1016/s0140-6736(15)01124-1
The paper
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016). Alzheimer’s Disease. The Lancet. https://doi.org/10.1016/s0140-6736(15)01124-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.